By Paul Ian Cross, PhD — Fact checked by Jill Seladi-Schulman, Ph.D.
In a new study published in the journal Science Advances, researchers used a unique gel containing human CAR T cells on the surgical wounds of mice after partial removal of the tumor.
The scientists reported that in nearly all instances, the CAR T cells effectively destroyed the remaining cancer cells, enabling the mice to survive when otherwise they would have died due to the return of the tumor.
These therapies involve collecting T cells from a person’s blood, modifying them in a laboratory setting, and then administering them back to the patient as a “living drug.”
Currently, there are six CAR T cell therapies that have been approved and are aimed at different types of blood cancers, offering new hope to people who have exhausted traditional treatment options.
Surgery can be an effective cure for solid tumor cancers that have not spread. However, it can be challenging for surgeons to determine where the tumor ends and healthy tissue begins. As a result, many types of cancer can recur after surgery due to remaining microscopic tumor cells.
To address this issue, the researchers tested a new approach that involves applying anti-tumor treatment to the remaining tissue margins right after the tumor is removed to eliminate any leftover cancer cells.
Targeting solid tumors with CAR T treatments has proven to be more challenging, partly due to the size of the tumors and the ways in which they protect themselves from the immune system.
However, recent research using a mouse model of brain cancer revealed that CAR T cells might be effective in eliminating any remaining cancer cells after surgical procedures.
In this study, the researchers applied this same technique to two other types of cancer that are difficult to treat: triple-negative breast cancer (which is devoid of the three main markers of breast cancer) and human pancreatic ductal carcinoma (the most prevalent form of pancreatic cancer).
Dr. Michael Hurwitz, an oncologist at the Yale Cancer Center and associate professor of internal medicine at the Yale School of Medicine in Connecticut who was not involved in the research, told Medical News Today that “this is a really interesting study about a novel way to prevent cancers from coming back after a cancer has been removed by surgery.
The idea is to infuse immune cells that have been engineered to recognize a protein on the surface of the cancer cells and kill them in order to destroy any residual tumor cells that might be left over after surgery.”
The researchers implanted tumors in mice that produce a protein called mesothelin. They then removed the tumors but left some behind, and implanted CAR-T cells that recognize mesothelin in some mice and CAR-T cells that recognize a different protein in others. The results showed that the mice that received anti-mesothelin CAR-T cells were cured, while the others were not, demonstrating the ability of the implanted cells to destroy the remaining tumor cells by recognizing the tumor.
Dr. Michael Hurwitz
Hurwitz explained that “this only worked well when the CAR-T cells were implanted in something called fibrin glue, which kept the cells at the site of the tumor removal (so they wouldn’t diffuse away).”
Dr. Parvin Peddi, a medical oncologist and associate professor of medical oncology at the Saint John’s Cancer Institute in California who is also not involved in this research, told MNT that “while it’s an early study in mice, these are intriguing results.”
“CAR T therapy is a form of immunotherapy. It has been approved for some patients with lymphoma and leukemia, but it has not yet been tested for patients with so-called “solid” cancers such as breast or pancreatic cancer. It can be toxic and requires careful monitoring, often in a hospital setting,” Peddi said.
Hurwitz explained that “this study would be considered a ‘proof of concept’ study.”
“That means that the study is really about showing that in theory, certain types of approaches to treatment might be possible,” he explained. “Developing this technology could lead to treatments someday that will make the likelihood of curing peoples’ cancers with surgery much higher.”
Saul Priceman, Ph.D., an associate professor at The City of Hope, a former recipient of an NCCN Foundation Young Investigator Award for research on the use of CAR T therapy in prostate cancer who was also not involved in the research, told MNT that “we know in many cases, surgery does not provide long term curative responses in patients with local but aggressive disease. This study broadens the potential for CAR T cell therapies using fibrin gels in targeting local disease in conjunction with primary cancer treatment options including surgery for more durable outcomes.”
This study further validates the potential for CAR T cells to be pushed to front-line treatment for early-stage diseases that have high recurrence rates following primary treatment (i.e. surgery), including head and neck, prostate, breast, pancreatic and ovarian cancers.
Saul Priceman
“The study also potentially addresses limitations of CAR T cells in terms of on-target and off-tumor toxicities with localized cell delivery using fibrin gels, such that patients may have improved safety profiles with this treatment with enhanced therapeutic responses,” Priceman explained.
The promising outcomes of this research have prompted researchers at the Perelman School of Medicine to plan a clinical trial for people with locally advanced breast cancer.
“I look forward to a study of CAR T cell therapy in humans in the setting of a clinical trial,” Peddi said.
Disclaimer
The information contained in South Florida Reporter is for general information purposes only.
The South Florida Reporter assumes no responsibility for errors or omissions in the contents of the Service.
In no event shall the South Florida Reporter be liable for any special, direct, indirect, consequential, or incidental damages or any damages whatsoever, whether in an action of contract, negligence or other tort, arising out of or in connection with the use of the Service or the contents of the Service. The Company reserves the right to make additions, deletions, or modifications to the contents of the Service at any time without prior notice.
The Company does not warrant that the Service is free of viruses or other harmful components
This article originally appeared here and was republished with permission.
